ArticleCureus2026
Histomorphological Spectrum of Soft Tissue Tumors at a Tertiary Care Hospital.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Soft tissue tumors (STT) comprise a broad and heterogeneous group of mesenchymal neoplasms with varied histological patterns and biological behavior. Accurate histomorphological evaluation and grading are essential for appropriate diagnosis, prognostication, and management, particularly in malignant cases. Objectives The present study was undertaken to analyze the histomorphological spectrum of soft tissue tumors encountered at a tertiary care hospital, to classify them according to the World Health Organization (WHO) 2022 classification, and to grade malignant tumors using the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grading system. Methods This combined retrospective and prospective descriptive study included 125 cases of soft tissue tumors received in the department of pathology of a tertiary care center over a one-year period. Clinical details were retrieved from requisition forms. Histopathological examination was performed on hematoxylin and eosin-stained sections, and tumors were classified based on WHO criteria. FNCLCC grading was applied to all malignant tumors. Immunohistochemistry (IHC) was performed wherever feasible to support diagnosis. Results Out of 125 cases, benign tumors constituted the majority at 107 cases (85.6%), followed by malignant tumors at 15 cases (12.0%) and intermediate tumors at three cases (2.4%). Patients ranged in age from five to 78 years, with a mean age of 39.6 ± 16.8 years. A slight male predominance was observed. Adipocytic tumors were the most common histological subtype, followed by fibroblastic and myofibroblastic tumors. Among malignant tumors, fibrosarcoma was the most frequent subtype. FNCLCC Grade 3 sarcomas were most common, indicating a predominance of high-grade malignancies. Conclusion Benign soft tissue tumors were far more common than malignant and intermediate tumors in the present study. Adipocytic tumors formed the largest histological category, while high-grade sarcomas predominated among malignant cases. Detailed histomorphological evaluation, supported by FNCLCC grading, remains crucial for the accurate classification and prognostic assessment of soft tissue tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.